UnknownPhase 3

The Letrozole Administration During Luteal Phase

China50 participantsStarted 2023-12

Plain-language summary

To investigate the effect of letrozole in patients who have high risk of ovarian hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were calculated between letrozole group and supporting treatment group.

Who can participate

Age range20 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. oocyte is more than or equal to 20;
✓. hCG injection on serum estradiol levels greater than or equal to 5000 pmol/L; 3. on the day of oocyte unilateral or bilateral ovarian diameter greater than or equal to 10 cm;

What they're measuring

The incidence of early OHSS

Timeframe: one year

Trial details

NCT IDNCT02686151

SponsorThe Affiliated Hospital of Inner Mongolia Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-03

Contact for this trial

Yu Wang, PhD

+86-18604718958 wuai1544@163.com

View on ClinicalTrials.gov More Ovarian Hyperstimulation Syndrome trials